Switch theme
Sign up to access all valuation multiples
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
1935
23.6K+
LTM Revenue $3.3B
LTM EBITDA $836M
$12.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cipla has a last 12-month revenue (LTM) of $3.3B and a last 12-month EBITDA of $836M.
In the most recent fiscal year, Cipla achieved revenue of $3.2B and an EBITDA of $936M.
Cipla expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cipla valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.3B | XXX | $3.2B | XXX | XXX | XXX |
| Gross Profit | $2.2B | XXX | $2.1B | XXX | XXX | XXX |
| Gross Margin | 66% | XXX | 67% | XXX | XXX | XXX |
| EBITDA | $836M | XXX | $936M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $705M | XXX | $705M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $612M | XXX | $617M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cipla's stock price is INR 1465 (or $17).
Cipla has current market cap of INR 1.18T (or $13.9B), and EV of INR 1.08T (or $12.6B).
See Cipla trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.6B | $13.9B | XXX | XXX | XXX | XXX | $0.75 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cipla has market cap of $13.9B and EV of $12.6B.
Cipla's trades at 4.0x EV/Revenue multiple, and 14.0x EV/EBITDA.
Equity research analysts estimate Cipla's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cipla has a P/E ratio of 22.6x.
See valuation multiples for Cipla and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.9B | XXX | $13.9B | XXX | XXX | XXX |
| EV (current) | $12.6B | XXX | $12.6B | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | 15.1x | XXX | 14.0x | XXX | XXX | XXX |
| EV/EBIT | 17.9x | XXX | 18.4x | XXX | XXX | XXX |
| EV/Gross Profit | 5.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 22.6x | XXX | 23.7x | XXX | XXX | XXX |
| EV/FCF | 33.1x | XXX | 32.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCipla's last 12 month revenue growth is 7%
Cipla's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Cipla's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cipla's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cipla and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | -2% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cipla acquired XXX companies to date.
Last acquisition by Cipla was XXXXXXXX, XXXXX XXXXX XXXXXX . Cipla acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cipla founded? | Cipla was founded in 1935. |
| Where is Cipla headquartered? | Cipla is headquartered in India. |
| How many employees does Cipla have? | As of today, Cipla has 23.6K+ employees. |
| Who is the CEO of Cipla? | Cipla's CEO is Mr. Umang Vohra. |
| Is Cipla publicy listed? | Yes, Cipla is a public company listed on BOM. |
| What is the stock symbol of Cipla? | Cipla trades under 500087 ticker. |
| When did Cipla go public? | Cipla went public in 1992. |
| Who are competitors of Cipla? | Similar companies to Cipla include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Cipla? | Cipla's current market cap is $13.9B |
| What is the current revenue of Cipla? | Cipla's last 12 months revenue is $3.3B. |
| What is the current revenue growth of Cipla? | Cipla revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Cipla? | Current revenue multiple of Cipla is 3.9x. |
| Is Cipla profitable? | Yes, Cipla is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cipla? | Cipla's last 12 months EBITDA is $836M. |
| What is Cipla's EBITDA margin? | Cipla's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Cipla? | Current EBITDA multiple of Cipla is 15.1x. |
| What is the current FCF of Cipla? | Cipla's last 12 months FCF is $381M. |
| What is Cipla's FCF margin? | Cipla's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Cipla? | Current FCF multiple of Cipla is 33.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
